Vertex Pharmaceuticals Inc (VRTX)

299.00
+5.05(+1.72%)
  • Volume:
    1,071,366
  • Day's Range:
    293.95 - 301.73
  • 52 wk Range:
    176.36 - 301.73
Trading near 52-week High

VRTX Overview

Prev. Close
293.95
Day's Range
293.95-301.73
Revenue
8.35B
Open
294.86
52 wk Range
176.36-301.73
EPS
12.49
Volume
1,071,366
Market Cap
76.61B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,660,283
P/E Ratio
23.28
Beta
0.45
1-Year Change
46.48%
Shares Outstanding
256,459,482
Next Earnings Date
02 Nov 2022
What is your sentiment on Vertex?
or
Vote to see community's results!

Vertex Pharmaceuticals Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Vertex Pharmaceuticals Inc Analysis

Vertex Pharmaceuticals Inc Company Profile

Vertex Pharmaceuticals Inc Company Profile

Employees
3900

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyBuyStrong BuyStrong Buy
Technical IndicatorsBuyStrong SellStrong BuyStrong BuyStrong Buy
SummaryBuyNeutralStrong BuyStrong BuyStrong Buy
  • I bought these shares through a company called Hoover Hyfield acting as managing brokers who seem to have disappeared from the scene!
    0
    • What made you want to use them as brokers?
      0
    • Error of judgement: expensive to!
      0
    • Hi Jas I've had the same experience with Hoover Hyfield. Did you get anywhere?
      0
  • test
    1
    • Captain Speaking --- Cabincrew get ready for 🛫✈ take off 🚀rocketdrive
      0
      • buy today tomorrow rocket
        0
    • Big NHS news. Massive contract.
      0
      • will it go higher????
        0